Titration of guideline directed medical therapy in a high-risk heart failure patients and impact on heart failure events

12 May 2024 (14:00 - 14:45)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Professor Nathan Mewton

Civils Hospices of Lyon, Lyon (France)

6 More presentations in this session

Presentation thumbnail

Initial experience with vericiguat treatment in real life. VERITA registry versus the VICTORIA study.

Doctor M. Groba Marco (Las Palmas de Gran Canaria, ES)

Abstract Slides Video

Presentation thumbnail

Outpatient treatment of heart failure decompensation with subcutaneous furosemide

Mrs A. Robles Mezcua (Malaga, ES)

Abstract Slides Video

Presentation thumbnail

Safety and efficacy of sacubitril/valsartan in patients with heart failure with mildly reduced or preserved EF after a worsening heart failure event based on diuretic use in PARAGLIDE-HF

Doctor S. Chatur (Boston, US)

Abstract Slides

Presentation thumbnail

Iron deficiency and supplementation in patients with heart failure: results from the IRON-HF international survey

Doctor F. Ballacci (Udine, IT)

Abstract Slides Video

Presentation thumbnail

Urinary sodium excretion dynamics in heart failure patients

Doctor H. Unlugenc (Izmir, TR)

Abstract Slides Video

Access the full session

Session thumbnail

Chronic heart failure - treatment 11

The Event

Event poster

Heart Failure 2024

12 May 2024 14:00 CET

You may be interested in

Congress Presentation

Optimising guideline-directed medical therapy in the sickest patients: how far can we go?

Congress Session

From evidence to practice: optimising guideline-directed therapy and prevention

Congress Presentation

Sudden cardiac death risk during guideline recommended medical therapy up-titration: where are we now?

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources